



Liver PPAR α is protective against NAFLD

Walter Wahli

Nanyang Technological University, Singapore

Abstract:

The liver is a key organ of metabolic homeostasis with functions that oscillate in response to food intake. Under the control of PPAR α in the mouse, the genes required for lipid catabolism are transcribed before birth so that the neonatal liver has a prompt capacity to extract energy from milk upon suckling. The mechanism involves a fetal glucocorticoid receptor (GR)-PPAR α axis in which GR directly regulates the transcriptional activation of PPAR α by binding to its promoter. In adult mouse, PPAR α deletion impairs fatty acid catabolism, resulting in hepatic lipid accumulation in preclinical models of steatosis. These findings underscore the relevance of hepatic PPAR α as a drug target for NAFLD as they show that PPAR α plays a central role in the clearance of free fatty acids released from adipocytes, the major source of lipid that accumulate in NAFLD. FGF21 is a hepatokine with beneficial metabolic effects, including control of sucrose preference. It is encoded in *Fgf21*, a unique hepatic gene that the transcription factors PPAR α and ChREBP both regulate to control sugar intake. In fact, ChREBP is required for the expression and secretion of hepatic FGF21 in response to carbohydrate intake.

Interestingly, experiments using hepatocyte-specific PPAR α knockout mice reveal a physiological role for PPAR α in the context of glucose challenge, as ChREBP is unable to induce *Fgf21* in the absence of hepatic PPAR α . These observations suggest that FGF21's glucose-mediated response is dependent on both ChREBP and PPAR α . Altogether, these findings underscore the relevance of hepatic PPAR α as a drug target for NAFLDs as they show that PPAR α plays a central role in the clearance of free fatty acids released from adipocytes, the major source of lipid that accumulate in NAFLD. Furthermore, they imply that drug targeting of PPAR α may exert part of its beneficial effects on metabolic homeostasis by supporting the ChREBP-induced loop controlling sweet preference via FGF21.

Biography:

Walter Wahli is Professor of Metabolic Disease at Lee Kong Chian School of Medicine, Nanyang Technological University and Imperial College London, Singapore. He is also the President of the Council of the Nestle Foundation for the study of problems of nutrition in the world. Prior to these, he was working at the University of Lausanne, Switzerland. He is recognized for his contributions to the area of energy metabolism. He is the Co-Discoverer of the transcription factors (PPARs), which are activated by fatty acids and eicosanoids and has provided fundamental insights into their multifaceted functions. His discoveries contributed in advancing the understanding of the molecular signaling of these lipids, which impact most key biological processes in vertebrates, including humans. He was awarded several prizes and recently received the Lifetime Achievement Award from the Faculty of Biology and Medicine, University of Lausanne.